Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia

Critical appraisal and patient focus

Osama O. Elkelany, Ryan C. Owen, Edward Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The evidence suggests that combination therapy for benign prostatic hyperplasia (BPH)-lower urinary tract symptoms (LUTS) using an a-blocker and a 5a-reductase inhibitor has become well accepted. The combination of daily tadalafl and an a-blocker has also demonstrated beneft. This paper addresses combination therapy with daily tadalafl and fnasteride for the treatment of BPH-LUTS. Our results demonstrate that use of tadalafl and fnasteride represents a logical extension of combination therapies. We analyze a landmark study by Casabé et al that demonstrates improved voiding symptoms as assessed by International Prostate Symptom Scores with a combination of tadalafl and fnasteride compared with fnasteride and placebo. Study patients had moderate to severe LUTS and prostate volumes >30 g. The additional beneft of improved erectile function as assessed by International Index of Erectile Function-erectile function domain scores with the addition of tadalafl was a secondary beneft. We propose that the ideal patient for combination therapy with tadalafl and fnasteride has a prostate volume >30 g and desires additional beneft over monotherapy. For these men, improved erectile function without sexual side effects was a secondary beneft.

Original languageEnglish (US)
Pages (from-to)507-513
Number of pages7
JournalTherapeutics and Clinical Risk Management
Volume11
DOIs
StatePublished - Mar 30 2015

Fingerprint

Finasteride
Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Prostate
Therapeutics
Oxidoreductases
Placebos
Tadalafil
evidence

All Science Journal Classification (ASJC) codes

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this

@article{4ff6de5690c4467b98efaa49c20007bc,
title = "Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: Critical appraisal and patient focus",
abstract = "The evidence suggests that combination therapy for benign prostatic hyperplasia (BPH)-lower urinary tract symptoms (LUTS) using an a-blocker and a 5a-reductase inhibitor has become well accepted. The combination of daily tadalafl and an a-blocker has also demonstrated beneft. This paper addresses combination therapy with daily tadalafl and fnasteride for the treatment of BPH-LUTS. Our results demonstrate that use of tadalafl and fnasteride represents a logical extension of combination therapies. We analyze a landmark study by Casab{\'e} et al that demonstrates improved voiding symptoms as assessed by International Prostate Symptom Scores with a combination of tadalafl and fnasteride compared with fnasteride and placebo. Study patients had moderate to severe LUTS and prostate volumes >30 g. The additional beneft of improved erectile function as assessed by International Index of Erectile Function-erectile function domain scores with the addition of tadalafl was a secondary beneft. We propose that the ideal patient for combination therapy with tadalafl and fnasteride has a prostate volume >30 g and desires additional beneft over monotherapy. For these men, improved erectile function without sexual side effects was a secondary beneft.",
author = "Elkelany, {Osama O.} and Owen, {Ryan C.} and Edward Kim",
year = "2015",
month = "3",
day = "30",
doi = "10.2147/TCRM.S80353",
language = "English (US)",
volume = "11",
pages = "507--513",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia

T2 - Critical appraisal and patient focus

AU - Elkelany, Osama O.

AU - Owen, Ryan C.

AU - Kim, Edward

PY - 2015/3/30

Y1 - 2015/3/30

N2 - The evidence suggests that combination therapy for benign prostatic hyperplasia (BPH)-lower urinary tract symptoms (LUTS) using an a-blocker and a 5a-reductase inhibitor has become well accepted. The combination of daily tadalafl and an a-blocker has also demonstrated beneft. This paper addresses combination therapy with daily tadalafl and fnasteride for the treatment of BPH-LUTS. Our results demonstrate that use of tadalafl and fnasteride represents a logical extension of combination therapies. We analyze a landmark study by Casabé et al that demonstrates improved voiding symptoms as assessed by International Prostate Symptom Scores with a combination of tadalafl and fnasteride compared with fnasteride and placebo. Study patients had moderate to severe LUTS and prostate volumes >30 g. The additional beneft of improved erectile function as assessed by International Index of Erectile Function-erectile function domain scores with the addition of tadalafl was a secondary beneft. We propose that the ideal patient for combination therapy with tadalafl and fnasteride has a prostate volume >30 g and desires additional beneft over monotherapy. For these men, improved erectile function without sexual side effects was a secondary beneft.

AB - The evidence suggests that combination therapy for benign prostatic hyperplasia (BPH)-lower urinary tract symptoms (LUTS) using an a-blocker and a 5a-reductase inhibitor has become well accepted. The combination of daily tadalafl and an a-blocker has also demonstrated beneft. This paper addresses combination therapy with daily tadalafl and fnasteride for the treatment of BPH-LUTS. Our results demonstrate that use of tadalafl and fnasteride represents a logical extension of combination therapies. We analyze a landmark study by Casabé et al that demonstrates improved voiding symptoms as assessed by International Prostate Symptom Scores with a combination of tadalafl and fnasteride compared with fnasteride and placebo. Study patients had moderate to severe LUTS and prostate volumes >30 g. The additional beneft of improved erectile function as assessed by International Index of Erectile Function-erectile function domain scores with the addition of tadalafl was a secondary beneft. We propose that the ideal patient for combination therapy with tadalafl and fnasteride has a prostate volume >30 g and desires additional beneft over monotherapy. For these men, improved erectile function without sexual side effects was a secondary beneft.

UR - http://www.scopus.com/inward/record.url?scp=84928106604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928106604&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S80353

DO - 10.2147/TCRM.S80353

M3 - Article

VL - 11

SP - 507

EP - 513

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -